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Abstract: Ankylosing spondylitis (AS) is a chronic, progressive disease characterized by 
inﬂ  ammation in the spine and sacroiliac joints which causes pain, stiffness and the potential 
for spinal ankylosis. It is associated with signiﬁ  cant functional impairment. It is common 
and since onset is often in young people, the burden of disease is considerable. Conventional 
treatment including non-steroidal antiinﬂ  ammatory drugs (NSAIDs) and physiotherapy have 
proven but limited efﬁ  cacy in controlling symptoms and preventing progression of spinal 
manifestations. Inﬂ  iximab, a chimeric monoclonal antibody which binds to and inhibits tumor 
necrosis factor alpha (TNFα), is highly effective in controlling disease activity in AS. In AS, 
inﬂ  iximab 5 mg/kg body weight is usually given as an infusion at weeks 0, 2 and 6, and then 
every 6–8 weeks. When inﬂ  iximab is used in combination with NSAIDs a rapid improvement 
in disease activity by at least 50% is seen in as many as 50% of AS patients. Inﬂ  iximab has 
been shown to have ongoing efﬁ  cacy for as long as regular infusions continue and is safe in 
the medium term. Magnetic resonance studies show major reductions in spinal inﬂ  ammation 
during treatment with inﬂ  iximab, however ongoing studies will assess if inﬂ  iximab has disease 
modifying effect in AS.
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Ankylosing spondylitis (AS) is a chronic systemic inﬂ  ammatory arthropathy that 
primarily affects the axial skeleton. It is the prototype of the spondyloarthritides 
(SpA), a group of diseases which includes psoriatic arthritis, inﬂ  ammatory bowel 
disease associated arthritis, reactive arthritis and undifferentiated spondyloarthritis. 
AS usually begins in adolescence or early adulthood, and is two to three times more 
common in men as in women (Khan 2002). The incidence varies with geographic 
location, affecting 0.1%–1.5% of the population (Boonen and van der Linden 2006). 
The major clinical features of AS are sacroiliitis and inﬂ  ammatory back pain, the 
later characterized by insidious onset before the age of 45 years, and worsening with 
inactivity and improving with physical activity. This is associated with impaired spinal 
mobility, with restriction of ﬂ  exion and extension of the lumbar spine and expansion 
of the chest. Other musculoskeletal features include peripheral arthritis and enthesitis 
(inﬂ  ammation at the sites at which ligaments and tendons insert into bone). These 
features are reﬂ  ected in the modiﬁ  ed New York criteria used to establish a diagnosis 
of AS (Table 1), which also recognizes radiological evidence of sacroiliitis as the 
hallmark of AS (van der Linden et al 1984). Extra-articular manifestations can include 
constitutional symptoms, acute anterior uveitis (AAU), spinal osteoporosis and aortic 
valve incompetence. The course of AS is variable but can lead to severe functional 
impairment due to spinal fusion and hip joint involvement or from extra-spinal mani-
festations. AS is also associated with unemployment and signiﬁ  cant ﬁ  nancial cost 
(Ward 2002; Mau et al 2005; Boonen and van der Linden 2006).
The goals of management of AS are to relieve pain, stiffness and fatigue, maintain 
spinal mobility and posture and avoid disability. For over 5 decades the mainstay of Biologics: Targets & Therapy 2007:1(2) 164
Grainger and Harrison
therapy has been long-term use of NSAIDs in combination 
with exercise and physical therapy (Dougados et al 2002). 
Although NSAIDs reduce spinal pain and improve function, 
and physical therapy improves spinal movement, many 
people with AS continue to have disabling symptoms due 
to active disease (Zochling et al 2006). There is limited 
evidence that traditional disease modifying antirheumatic 
drugs (DMARDs) including methotrexate and sulfasalazine 
may improve peripheral arthritis in AS and sulfasalazine may 
have a modest beneﬁ  t for inﬂ  ammatory back pain in patients 
with relatively mild disease (Braun, Zochling, et al 2006). In 
this context, treatment of AS with biological agents which 
block tumor necrosis factor alpha (TNFα) has been a key 
therapeutic advance.
TNFα is a pivotal regulator of the expression of other 
pro-inﬂ  ammatory cytokines and is a key mediator of synovial 
and systemic inﬂ  ammation (Feldmann 2001). Anti-TNFα 
therapy with the monoclonal antibody inﬂ  iximab (Remicade; 
Centocor Inc., Malvern. PA) was initially demonstrated to be 
highly effective in treating rheumatoid arthritis refractory to 
traditional DMARDs (Maini et al 1998, 1999; Lipsky et al 
2000) and refractory ﬁ  stulating Crohn’s disease (Present et al 
1999). As SpA can be seen in patients with inﬂ  ammatory 
bowel disease, TNFα seemed a potential therapeutic target 
in AS and subsequently patients with Crohn’s disease treated 
with inﬂ  iximab were shown to have an improvement in the 
peripheral arthritis of inﬂ  ammatory bowel disease associated 
SpA (Van den Bosch, Kruithof, De Vos, et al 2000). In addi-
tion demonstration that the cellular inﬁ  ltrate in sacroiliitis 
had abundant TNFα messenger RNA (Braun et al 1995) and 
that TNFα was elevated in the serum (Gratacos et al 1994; 
Toussirot et al 1994) and synovial tissue (Canete et al 1997) of 
patients with SpA justiﬁ  ed pilot studies of inﬂ  iximab therapy 
for AS. Open studies performed simultaneously in Ghent (Van 
den Bosch, Kruithof, Baeten, et al 2000) and Berlin (Brandt 
et al 2000) showed rapid and persistent reduction in symptoms 
of AS with inﬂ  iximab therapy which were conﬁ  rmed in further 
open label studies (Stone et al 2001; Maksymowych et al 2002; 
Breban et al 2002) and observational cohort studies (Brandt 
et al 2001; Temekonidis et al 2003) using inﬂ  iximab in patients 
with active AS refractory to treatment with NSAIDs.
Inﬂ  iximab
Infliximab is a chimeric IgG1 κ monoclonal antibody, 
composed of human constant regions and the TNFα-speciﬁ  c 
murine variable regions (Knight et al 1993). Inﬂ  iximab is 
produced by a recombinant cell line cultured by continuous 
perfusion and is puriﬁ  ed by a series of steps that includes 
measures to inactivate and remove viruses. Inﬂ  iximab neu-
tralizes the biological activity of TNFα by binding with high 
afﬁ  nity to the soluble and transmembrane forms of TNFα, 
preventing association of TNFα with its receptors (Knight 
et al 1993). Cells expressing transmembrane TNFα bound 
by inﬂ  iximab are lysed in vitro by both complement and 
cell mediated lysis (Scallon et al 1995). Inﬂ  iximab inhibits 
the functional activity of TNFα in a wide variety of in vitro 
bioassays utilizing human ﬁ  broblasts, endothelial cells, 
neutrophils, B and T lymphocytes and epithelial cells (Siegel 
et al 1995). It is supplied as a sterile, white, lyophilized 
powder, reconstituted with sterile water for intravenous infu-
sion, usually over 1–2 hours. In AS the conventional dose 
regimen is 5 mg/kg given initially at 0, 2 and 6 weeks, then 
every 6–8 weeks. Inﬂ  iximab is licensed for use in adults; it 
has not been tested in children.
Considerations relevant
to understanding clinical trials in AS
Interpreting clinical trials in AS requires an introduction to 
classiﬁ  cation and outcome measures relevant in AS, includ-
ing potential limitations. Entry criteria require a deﬁ  nite 
diagnosis of AS according to modiﬁ  ed New York criterion 
(Table 1), thus all enrolled patients have radiological evidence 
of sacroiliitis of at least grade 2 bilaterally (early sacroiliitis 
with minor sclerosis, limited erosions and joint space nar-
rowing) or grade 3 unilaterally (deﬁ  nite sacroiliitis with 
severe sclerosis, clear-cut erosions, joint space narrowing and 
some ankylosis). As sacroiliitis often takes years to develop, 
Table 1 Modiﬁ  ed New York criteria for ankylosing spondylitisa
A. Diagnosis
 1. Clinical  criteria
   a .    Low back pain and stiffness for more than 3 months which 
improves with exercise, but is not relieved by rest.
   b .    Limitation of motion of the lumbar spine in both the sagittal 
and frontal planes.
   c .    Limitation of chest expansion relative to normal values cor-
rected for age and sex.
 2. Radiological  criterion
   a .    Sacroiliitis grade 2 bilaterally or sacroiliitis grade 3–4 
unilaterally.
B. Grading
 1.   Deﬁ  nite ankylosing spondylitis if the radiological criterion is asso-
ciated with at least one clinical criterion.
 2.   Probably ankylosing spondylitis if: 
      a.  Three clinical criterion are present.
   b .    The radiological criterion is present without any signs or 
symptoms satisfying the clinical criteria. (other causes of 
sacroiliitis should be considered).
a Van der Linden et al 1984.Biologics: Targets & Therapy 2007:1(2) 165
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results from these trials can only be applied to patients 
with established, longstanding disease. Expert panels have 
acknowledged that this may exclude patients with early AS 
who may still beneﬁ  t greatly from treatment with inﬂ  iximab 
(Braun, Pham, et al 2003) and the development of diagnostic 
criteria which include MRI to identify patients with early 
disease remains an area of active research. For the purpose of 
enrolment most clinical trials deﬁ  ne active disease as a Bath 
Ankylosing spondylitis activity index (BASDAI) of 4. Key 
outcome assessment instruments are outlined in Table 2.
Response to treatment is generally measured as absolute 
reduction of any one of the outcomes measures by a pre-
deﬁ  ned amount (eg, a reduction in BASDAI of  2) or as a 
percentage reduction of a composite score. The Assessments 
in Ankylosing Spondylitis (ASAS) Working Group has 
deﬁ  ned and validated a composite of disease activity and 
disability called ASAS 20 which requires an improvement 
of 20% or more and absolute improvement of more than 
10 units on a 0–10 scale in the 3 of the 4 domains of patient 
global, pain, function and inﬂ  ammation and no deterioration 
in the remaining domain (Anderson et al 2001). Although 
not speciﬁ  cally validated, many trials report proportions of 
patients reaching ASAS 50 or ASAS 70 (patients reaching a 
50% or 70% improvement in the ASAS 20 domains).
Pivotal controlled trials 
in the treatment of AS
Braun et al conducted a 12-week, multi-center, randomized-
controlled trial (RCT) of infliximab versus placebo in 
70 patients with active AS (Braun et al 2002). The primary 
end point was a 50% reduction of disease activity (measured 
as BASDAI). Fifty-three percent of inﬂ  iximab-treated patients 
achieved this end-point compared with 9% of placebo-
treated patients, a highly statistically signiﬁ  cant difference 
(p  0.001). Improvement was rapid in the inﬂ  iximab-treated 
group with 41% of patients having 50% improvement within 
2 weeks. There were also similar improvements in function, 
spinal mobility and quality of life for the inﬂ  iximab group. 
Inﬂ  iximab-treated patients also had reduced use of NSAIDs 
and reductions in C-reactive protein (CRP) and erythrocyte 
sedimentation rate. Although infliximab was generally 
well tolerated, three patients had serious adverse events 
and were withdrawn from this short study. These included 
disseminated tuberculosis, high fever and lymphadenopathy 
with pulmonary inﬁ  ltrates. Twenty of these patients enrolled 
at one centre had spinal magnetic resonance imaging (MRI) 
of the spine conducted at baseline and week 12, in part to 
evaluate a new scoring system (Braun, Baraliakos, et al 
2003). Seventy-ﬁ  ve percent of patients had active spinal 
lesions, deﬁ  ned as vertebral bone marrow edema and/or 
erosions, with a 40% improvement seen in the inﬂ  iximab 
group and 6% in placebo group. Reduction in MRI evidence 
of spinal inﬂ  ammation had a strong correlation with the 
observed clinical improvement in inﬂ  iximab-treated patients. 
At the 12-week conclusion of this trial the 69 completing 
patients all received treatment with inﬂ  iximab 5 mg/kg every 
6 weeks and have been followed-up in an open extension 
trial, the results of which are discussed below.
A contemporaneous RCT included 40 patients with a 
variety of SpA and included 11 patients with AS and a total 
of 21 patients with axial disease (Van Den Bosch et al 2002). 
Similar reductions in BASDAI, BASFI and spinal pain were 
observed at 12 weeks in these patients.
The ASSERT trial is the largest placebo-controlled trial 
of inﬂ  iximab for AS, randomizing 279 patients in multiple 
centres to placebo or inﬂ  iximab 5 mg/kg at baseline 2, 6, 12 
and 18 weeks (van der Heijde et al 2005). The primary end 
point was achievement of ASAS 20 at 6 months. The patients 
were typical of those with active AS, consisting of 80% men 
with a median age of 40 years and median disease duration 
of almost 9 years. At 24 weeks 61% of the inﬂ  iximab group 
had achieved an ASAS 20 response, compared to 19% in the 
placebo arm (p  0.001). Again patients receiving inﬂ  iximab 
also showed improvement within 2 weeks, which was sus-
tained through the study period. Signiﬁ  cant improvements 
were observed in the all outcomes measured including disease 
activity (BASDAI), function (BASFI), mobility (BASMI), 
chest expansion and quality of life (physical component 
of SF-36). Although adverse events were common in both 
treatment groups (82.2% of patients receiving inﬂ  iximab and 
72.0% of patients receiving placebo) most were mild and did 
not mandate withdrawal from the trial. The commonest were 
infections (43% inﬂ  iximab versus 36% placebo) and infu-
sion reactions (11% inﬂ  iximab versus 9.3% placebo). Seven 
patients (3.5%) in the inﬂ  iximab group had severe adverse 
events, with the one withdrawal due to myelitis. MRI out-
comes have also been evaluated in a sub-set of the patients 
enrolled in the ASSERT trial (Braun, Landewe et al 2006). 
A total of 266 patients had spinal MRI at baseline and 24 
weeks, 194 in the inﬂ  iximab group and 72 in the placebo 
group. About 80% of patients had at least one active spinal 
lesion on MRI at baseline. Images were scored according to 
a MRI activity score (Braun, Baraliakos, et al 2003), which 
assigns a score of 0–6 for vertebrae from C2 to S1 on the 
presence and extent of bone marrow edema and erosions 
to give a total score of 0–138. Compared to placebo, more Biologics: Targets & Therapy 2007:1(2) 166
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patients in the inﬂ  iximab group showed a reduction in 
inﬂ  ammation score and patients in the inﬂ  iximab group had 
a signiﬁ  cantly greater improvement in total MRI Activity 
Scores from baseline to week 24 (5.0 ± 6.2, mean ± SD, 
median 2.7) than did patients in the placebo group (0.6 ± 3.4, 
median 0.0) (p  0.001).
All of these RCTs required withdrawal of DMARDs. Oral 
corticosteroids were discontinued before screening, however 
patients were permitted to continue baseline dose of NSAIDs. 
This is in contrast to treatment of RA with inﬂ  iximab, which 
requires concomitant treatment with methotrexate, in part to 
reduce the incidence of human antibodies against the chimeric 
Table 2 Outcome measures commonly used in trials of therapy in ankylosing spondylitis
Tool Dimension  measured  Deﬁ  nition
BASDAI  Disease activity  A composite index that includes 
Bath Ankylosing     questions on fatigue, axial 
spondylitis disease     pain, peripheral arthritis, 
activity indexa    enthesitis and severity and 
    duration of stiffness, measured 
    on a visual analogue scale 
    (VAS) of 0–10.
BASFI  Function  A self-assessment instrument 
Bath Ankylosing     consisting of 8 questions 
spondylitis functional     regarding function in AS and 
indexb   two  questions  reﬂ  ecting the 
    patient’s ability to cope with 
    everyday life, measure on a VAS
BASMI  Mobility  A composite index of clinical 
Bath Ankylosing     measurement of mobility 
spondylitis metrology     including tragus to wall, lumbar 
indexc   ﬂ  exion, cervical rotation, 
   lumbar  side  ﬂ  exion and inter 
    malleolar distance, each 
    measured on a 0–3 scale.
ASAS 20d  Includes domains of   A composite of disease activity 
  patient global, pain,   and disability, an improvement 
  function and   of 20% or more, and absolute 
 inﬂ  ammation  improvement of 10 or more 
    units on a scale of 0–100 scale 
    in 3 or more of the following 
   4  domains;
    1. Patient global 
     assessment  (by  VAS 
     global  assessment)
    2. Pain assessment 
      (average of VAS total 
      and nocturnal pain 
     scores)
    3. Function (represented 
     by  BASFI) 
   4.  Inﬂ  ammation (average 
      of the BASDAI’s last two 
     VASs  concerning 
     morning  stiffness, 
      intensity and duration) 
    and an absence of deterioration 
    in the potential remaining 
    domain (deterioration deﬁ  ned 
    as 20% worsening). 
aGarrett et al 1994
bCalin et al 1994
cJenkinson et al 1994
dAnderson et al 2001Biologics: Targets & Therapy 2007:1(2) 167
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parts of the molecule (Human anti-chimera antibodies or 
HACA) (Moreland et al 1996). HACA are thought to be 
responsible for infusion reactions (Baert et al 2003). In a 
30-week double-blind RCT patients treated with inﬂ  iximab 
and low dose methotrexate had a similar low incidence of 
infusion reactions to patients treated with inﬂ  iximab alone, 
although the incidence of HACA antibodies in each treatment 
group was not assessed (Marzo-Ortega et al 2005).
Open label extensions
Reports on the open-label extension of the pivotal RCTs of 
inﬂ  iximab therapy for AS show a durability of response. In the 
extension of the original 3-month RCT, Braun et al reported 
that of the original 69 patients who received inﬂ  iximab after 
the 12 week end point, 49 (71%) continued inﬂ  iximab for 
2 years (Braun, Brandt, et al 2005), 43 (62%) for 3 years 
(Braun, Baraliakos, Brandt, et al 2005) and 41 (59.4%) for 
5 years (Baraliakos et al 2006). All improvements in disease 
activity were sustained and almost 60% of patients maintained 
an ASAS 50 over 3 years. Outcomes for 5 years were recently 
reported in abstract form, conﬁ  rming a sustained response 
(Barakiakos et al 2006). During the 3-year follow-up up to 
96% of patients had adverse events, although these were 
generally mild with only 11 patients discontinued therapy 
due to adverse events (Braun, Baraliakos, Brandt et al 2005). 
Although the long-term efﬁ  cacy of inﬂ  iximab has been dem-
onstrated, unfortunately there is a rapid loss of response with 
discontinuation. Over 60% of patients who have previously 
had a sustained response to therapy relapse within 4 months of 
cessation of inﬂ  iximab infusions (Baraliakos, Listing, Brandt, 
et al 2005). Fortunately all patients retreated responded with 
resumption of infusions.
Other outcomes
An important outcome measure in trials of therapy for AS is 
the ability to prevent radiographic progression. Improvement 
of active spinal lesions over short periods after treatment 
with inﬂ  iximab has been demonstrated by MRI as already 
discussed but chronic spinal changes are better assessed 
by plain radiography (Wanders et al 2004). Comparison 
of patients treated for 2 years with inﬂ  iximab with patients 
from an AS cohort followed-up for 2 years showed a small, 
non-signiﬁ  cant reduction in radiological changes on lateral 
lumbar and cervical spine views in the inﬂ  iximab treated 
group as measured with modiﬁ  ed Stoke ankylosing spondy-
litis spine score (Baraliakos, Listing, Rudwaleit, et al 2005), 
despite older age, longer disease duration and higher level 
of radiographic damage at baseline. Although promising, 
larger studies over longer periods will be required to assess 
the disease modifying effects of inﬂ  iximab.
Enthesitis is one of the most common extra-axial features 
of the SpA. Neither of the two major RCT enrolling patients 
with AS demonstrated signiﬁ  cant reductions in enthesitis or 
swollen joint count in inﬂ  iximab treated patients, perhaps 
because the prevalence of extra-axial inﬂ  ammation was very 
low at baseline in both studies (Braun et al 2002, van der 
Heijde et al 2005). However a 12-week RCT of 40 patients 
with a variety of SpA randomized to receive inﬂ  iximab at 
standard AS dose or placebo did show inﬂ  iximab treatment 
was associated with a statistically signiﬁ  cant reduction in 
peripheral joint pain and tenderness (Van Den Bosch et al 
2002). Inﬂ  iximab has also induced a rapid and complete 
clinical and ultrasonographic resolution of refractory, erosive 
calcaneal enthesitis in two HLA-B27+ patients after induction 
treatment with inﬂ  iximab 3 mg/kg (D’Agostino et al 2002).
The incidence of AAU appears to be reduced during treat-
ment with inﬂ  iximab. Data on 397 patients enrolled in RCT 
of TNFα-inhibitors showed patients receiving placebo had 
a mean 15.6 ﬂ  ares of AAU/100 patient years compared to 
3.4/100 patient years for inﬂ  iximab treated patients (Braun, 
Baraliakos, Listing, et al 2005).
AS can occur in the context of psoriasis, which in itself 
is a potentially disabling condition. A Phase III RCT inpa-
tients with moderately severe psoriasis showed inﬂ  iximab 
monotherapy was highly effective in treating both skin and 
nail psoriasis (Reich et al 2005).
Osteoporosis leading to spinal fracture is a recognised late 
complication of AS (Khan 2002). Two recent studies have 
reported improvements in bone mineral density (BMD) in 
patients with AS treated with inﬂ  iximab (Allali et al 2003; 
Marzo-Ortega et al 2005). Allai et al (2003) measured signiﬁ  -
cant improvements in BMD at the spine (3.6%, p = 0.001) and 
total hip (2.2%, p = 0.0012) in 29 patients with SpA treated 
with inﬂ  iximab for 6 months. A RCT comparing treatment 
with inﬂ  iximab and methotrexate versus methotrexate alone 
in 42 patients with AS recorded a 1.9% increase in BMD 
at the hip (p = 0.04) in the inﬂ  iximab group after 30 weeks 
with non-signiﬁ  cant increases in the femoral neck and spine 
(Marzo-Ortega et al 2005). In these studies approximately 
20% of patients were taking systemic glucocorticoids but 
these were not discontinued.
Inﬂ  iximab treatment of AS has impacts on socio-economic 
outcome measures. Over the relatively short 6-month period 
of an RCT, inﬂ  iximab treatment was associated with reduc-
tions in work absenteeism and work disability (van der Heijde 
et al 2006). In the open label extension of the Braun study Biologics: Targets & Therapy 2007:1(2) 168
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there was a reduction of hospital admissions from 41% in 
the 12 months prior to enrollment to 10% in the patients 
completing 2 years of inﬂ  iximab therapy (Listing et al 2004). 
In addition the sub-group of completers who were in paid 
employment there was a reduction in work absenteeism with 
the mean number of days sick leave per annum reducing from 
31.5 to 12.5 at 1 year and 4.7 days at 2 years. The cost sav-
ings of inﬂ  iximab therapy were estimated at almost  5000 
for each treated patient per year.
Dose
There are no formal dose ﬁ  nding studies for inﬂ  iximab in 
AS. The 5 mg/kg dose was chosen as this dose is standard for 
patients with Crohn’s disease and on the basis of a small study 
which suggested 5 mg/kg was more effective than 3 mg/kg 
(Braun et al 2002). Indeed in a cohort of 30 patients with 
SpA with axial involvement treated 6-weekly with 3 mg/kg 
inﬂ  iximab, two-thirds of patients required an increase in dose 
or reduction in interval to achieve or maintain a response 
(Sidiropoulos et al 2005). In a Canadian cohort including 
8 patients treated for 1 year with 3 mg/kg inﬂ  iximab every 
8 weeks, these patients had maintenance of initial response 
but two patients required an increased dose of inﬂ  iximab 
to sustain the response (Maksymowych et al 2002). In a 
pilot study of 21 patients with a variety of AS related SpA 
a dosage regimen of 5 mg/kg of inﬂ  iximab every 14 weeks 
ultimately resulted in almost 80% of patients experiencing 
relapse of disease activity prior to the next infusion (Kruithof 
et al 2002). This suggests the 14-week interval was too long. 
A dosage regimen of 5 mg/kg every 8 weeks has shown sus-
tained achievements of ASAS 50 after 1 year of treatment. 
Thus most patients will require a dose of 3–5 mg/kg given 
6–8 weekly for an adequate and sustained clinical response 
although there may be a need to individualize dosage or 
interval based on response.
Safety
The major immunomodulating effect of inﬂ  iximab on the 
immune system raises concerns about the risk of infection, 
autoantibodies and tumors. The infectious risk associated 
with inﬂ  iximab has been systematically assessed in a cohort 
of 107 patients with SpA with observations extending 
over 191.5 patient years of treatment (Baeten et al 2003). 
Eight severe infections were observed, including two 
cases of reactivation of tuberculosis, three retropharyn-
geal abscesses, one episode of culture-negative sepsis-like 
syndrome and two procedure-related infections. Reacti-
vation of tuberculosis was also reported in a previously 
discussed RCT (Braun et al 2002). The risk of reactivation 
of tuberculosis during treatment with inﬂ  iximab is well 
documented. Of note, this often occurs within 12 weeks of 
commencement of therapy, with in excess of 50% of cases 
being extra-pulmonary, 25% disseminated and almost 50% 
requiring a biopsy for diagnosis (Keane et al 2001). Current 
guidelines recommend screening for active or latent tuber-
culosis when considering treatment with a TNFα-inhibi-
tor and treatment of latent tuberculosis with prophylactic 
isoniazid for at least 2 months prior to commencement of 
inﬂ  iximab, with completion of 6–9 months of isoniazid 
therapy (American Thoracic Society 2000; British Thoracic 
Society 2005). Patients treated with inﬂ  iximab, and their 
physicians, should be aware of the increased risk of serious 
infection and prompt assessment of any symptoms which 
may suggest infection is warranted. Inﬂ  iximab therapy is 
relatively contraindicated in situations associated with an 
increased risk of infection including: chronic leg ulceration, 
septic arthritis of a native joint within 12 months, sepsis of a 
prosthetic joint within 12 months or indeﬁ  nitely if prosthe-
sis remains in situ, persistent or recurrent chest infections 
(eg, bronchiectasis), and presence of an indwelling urinary 
catheter (Braun, Pham, et al 2003).
Clinical trials have shown that inﬂ  iximab may induce 
autoantibodies such as antinuclear antibodies (ANA) and 
anti dsDNA antibodies (Charles et al 2000). The occurrence 
of these antibodies during inﬂ  iximab therapy for AS has not 
been systematically addressed. In one placebo-controlled 
trial enrolling patients with SpA, 17% were ANA positive 
and none dsDNA positive at baseline but after 34-weeks of 
inﬂ  iximab therapy 89% were ANA positive and 17% dsDNA 
positive (Van Den Bosch et al 2002). No patients had any 
clinical evidence of lupus-like disease.
Asymptomatic elevation in liver transaminases are com-
monly observed during treatment with inﬂ  iximab and rare 
cases of acute liver failure and autoimmune hepatitis have 
been reported (Inﬂ  iximab Product Information, Centocor, 
Malvern PA). Cytopenias have also been observed, although 
casual association has not been established.
Other contraindications to inﬂ  iximab therapy include preg-
nancy or inadequate contraception in a women of child-bearing 
potential, breastfeeding, history of lupus or multiple sclerosis, 
malignancy other than basal cell carcinoma and those treated 
more than 10 years previously (Braun, Pham, et al 2003)
Biological modulation
Although there are no studies of a pure AS cohort, there are 
data regarding the biological effects of inﬂ  iximab therapy Biologics: Targets & Therapy 2007:1(2) 169
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in patients with SpA. Patients with SpA appear to have Th2 
polarization with decreased T-cell production of IFNγ and 
IL-2 and increased IL-10 (Yin et al 1999; Baeten, Kruithof, 
et al 2001; Baeten, Van Damme, et al 2001). Treatment 
with inﬂ  iximab induced a rapid and sustained increase in 
T-cell synthesis of IFNγ and IL-2 and transient decrease in 
IL-10 production (Baeten, Kruithof, et al 2001) restoring 
Th1/Th2 balance. This data supports the hypothesis that 
inﬂ  iximab reverses the anergic state of Th1 cells. At a tissue 
level repeated synovial biopsy has allowed an insight into 
histological changes in synovial pathology in peripheral 
joints in SpA patients with active synovitis after treatment 
with inﬂ  iximab. After 12 weeks inﬂ  iximab reduced syno-
vial layer thickness, endothelial activation (E-selection or 
VCAM-1) and cellular inﬁ  ltration by neutrophils, macro-
phages and T cells (Baeten, Kruithof, et al 2001; Kruithof 
et al 2005). Synovial levels of matrix metalloproteinase-3 
(MMP-3) and tissue inhibitors of matrix metalloproteinases 
(TIMP) are also elevated in SpA synovium and treatment 
with inﬂ  iximab rapidly downregulates synovial expres-
sion of MMP-3 and TIMP and serum MMP-3 (Vandooren 
et al 2004). Further analysis has shown that reduction in 
lining and sub-lining macrophages and reduced immature 
macrophages, sub-lining matrix MMP-3 and neutrophil 
inﬁ  ltration are accurate early predictors of response to 
treatment, performing as well as changes in acute phase 
reactants (Kruithof et al 2006).
Cost effectiveness
As a recombinant biological agent, inﬂ  iximab therapy is 
expensive. Despite the expense, cost-effectiveness model-
ling in two health-care systems suggest the clinical beneﬁ  ts 
and improvement in quality of life with inﬂ  iximab lead to 
lower disease-associated costs than standard care (Kobelt 
et al 2004, 2006) and modeling for long-term therapy 
assuming progression of BASFI sees a further reduction in 
the cost per quality adjusted life year. Longer term data on 
disease progression of AS during treatment with inﬂ  iximab 
is required to conﬁ  rm this hypothetical data, in addition to 
measurements of savings in in-direct costs related to work 
disability and AS-related illness.
Current indications
A consensus statement developed by the ASAS working 
group gives clear recommendations, based on published 
literature and expert opinion, about the indication for 
anti-TNFα therapy in AS (Braun, Pham, et al 2003; 
Braun, Davis, et al 2006). For the initiation of therapy 
the recommendations are 1. A diagnosis of deﬁ  nitive AS 
based on the modiﬁ  ed New York criteria; 2. Presence 
of active disease for at least 4 weeks deﬁ  ned by both a 
sustained BASDAI of at least 4 and expert opinion based 
on clinical features, acute phase reactants, and imaging 
modalities; 3. Presence of refractory disease deﬁ  ned by 
failure of at least two NSAIDs during a single 3-month 
period, failure of intra-articular steroids if indicated, 
and failure of sulfasalazine in patients with peripheral 
arthritis; 4. Application and implementation of the usual 
precautions and contraindications for biological therapy. 
Discontinuation is recommended if there is a failure to 
reach at least a 50% or 2-unit improvement (on a 0–10 
scale) of the BASDAI at 6–12 weeks or if expert opinion 
suggests cessation. Most countries will develop local 
guidelines for therapy, which may be inﬂ  uenced by cost 
considerations as well as published literature. Retrospec-
tive analysis of major RCTs suggests that a response to 
therapy may be predicted by shorter disease duration and 
less functional disability (Rudwaleit, Listing, et al 2004) 
however the patients included in this analysis had very 
high disease activity at baseline and these conclusions 
may not be appropriate to generalize to a real-world 
treatment situation. A major problem in treatment of AS 
is the long delay between onset of symptoms and diag-
nosis (Khan 2002). This is of particular relevance when 
response to inﬂ  iximab therapy may be improved when 
therapy is commenced early. Rudwaliet, van der Heijde 
et al (2004) have proposed a clinical algorithm based on 
the presence of inﬂ  ammatory back pain and assigning 
likelihood ratios for diagnosis based on the presence of 
other features of SpA. The presence of inﬂ  ammatory back 
pain and two or three other features of SpA (including 
enthesitis, alternating buttock pain, peripheral arthritis, 
dactylitis, AAU, psoriasis, family history of SpA and 
response to NSAIDs) gave a positive test probability of 
over 90% for the diagnosis of early SpA. Further clinical 
trials of inﬂ  iximab in patients with probable early AS will 
be necessary to conﬁ  rm therapy is appropriate for these 
patients but a clinical and perhaps radiological beneﬁ  t 
seems highly probable.
The advent of inﬂ  iximab has dramatically increased 
the therapeutic options for people affected by AS. Inﬂ  ix-
imab is highly effective in treating active AS refractory to 
NSAIDs and some available radiological data suggest a 
disease modifying effect. Limitations of therapy include 
potential side effects, particularly serious infection, the 
cost and the undetermined beneﬁ  t in early disease. The cost Biologics: Targets & Therapy 2007:1(2) 170
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effectiveness of long-term inﬂ  iximab therapy remains to 
be determined.
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